Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eisai Ltd ADR (OP: ESALY ) N/A UNCHANGED Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 61.51 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why April 24, 2024 Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA... Via Benzinga Exposures Product Safety European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab March 22, 2024 Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. Via Benzinga Performance More News Read More Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision March 08, 2024 Via Benzinga Exposures Product Safety Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says February 14, 2024 Via Benzinga Why Is Biogen Stock Trading Lower On Tuesday? February 13, 2024 Via Benzinga Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns January 12, 2024 Via Benzinga Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer December 08, 2023 Via Benzinga Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others November 21, 2023 Via Benzinga Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides November 08, 2023 Via Benzinga Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage October 13, 2023 Via Benzinga Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Via Benzinga LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly October 10, 2023 Via Benzinga Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories September 25, 2023 Via Benzinga Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi September 25, 2023 Via Benzinga Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer September 22, 2023 Via Benzinga Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial August 25, 2023 Via Benzinga Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. August 01, 2023 Via The Motley Fool Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi July 10, 2023 Via MarketBeat Exposures Product Safety Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts July 07, 2023 Via Benzinga Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed June 14, 2023 Via Benzinga FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories June 13, 2023 Via Benzinga Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources June 13, 2023 Via Benzinga Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote June 12, 2023 Via Benzinga Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low June 12, 2023 Via Benzinga Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' June 08, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.